Skip to main content
OpenTrials
Completed

NCT Number: NCT01280175

Foster With or Without Charcoal Block or Aerochamber Plus

The purpose of this study is to evaluate the systemic exposure of BDP, its metabolite beclomethasone 17-monopropionate (B17MP) and formoterol after inhalation of BDP/Formoterol 100/6 µg pMDI combination (CHF1535) using the standard actuator and charcoal block technique or using a Spacer (AeroChamber Plus, Trudell) in comparison with inhalation using the standard actuator

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

CROSS Research SA

Arzo, Via F.A. Giorgioli, 14, 6864, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sex: male
  • 18≤age≤45 years old
  • BMI: 18≤BMI≤28 kg/m2
  • Non-smokers
  • Vital signs: SBP 100-139 mmHg, DBP 50-89, HR 50-90 bpm, measured after 5 min of rest in the sitting position
  • Full comprehension: ability to use correctly the pMDI preparations; ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study
  • Informed Consent: signed written informed consent prior to inclusion in the study.

Exclusion criteria

  • ECG (12 leads): clinically relevant abnormalities and/or QTc >450 msec;
  • Physical findings: clinically relevant abnormal physical findings, which could interfere with the objectives of the study; in particular any abnormality in the lung functionality: FEV1 <80% predicted values according to European Respiratory Society basing upon Quanjer et al. (25)
  • Laboratory analyses: clinically relevant abnormal laboratory values indicative of physical illness; in particular positive HIV1 and HIV2 serology and/or positive hepatitis serology indicating acute or chronic hepatitis B or C
  • Allergy: ascertained or presumptive hypersensitivity to the active principles and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
  • Diseases: relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, that may interfere with the aim of the study
  • Medications: medication, including OTC, during 2 weeks before the start of the study. Any known enzyme inducing drug or enzyme inhibitor must be stopped at least 2 months before study start
  • Investigative drug trials: participation in the evaluation of any drug within 3 months prior to the screening
  • Blood donation: blood donations during the 3 months prior to this study
  • Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>2 drinks/day, defined according to USDA Dietary Guidelines 2005 (26)], caffeine (>5 cups coffee/tea/day) abuse or smoking
  • Abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits within the past 4 weeks.

Treatment and study plan

charcoal block

Procedure

Aerochamber Plus spacer

Device

pMDI standard actuator

Drug

Primary outcomes

  1. Systemic exposure and lung bioavailability of BDP, B17MP and formoterol.

    Time frame: from pre-dose until 12 h post-dose

Secondary outcomes

  1. General tolerability and safety of the test product.

    Time frame: from pre-dose until 12 h post-dose

Sponsors and collaborators

Lead sponsor

Chiesi Farmaceutici S.p.A.

Industry

Collaborators

  • Cross Research S.A.

Registry information

Official study title

Pharmacokinetics and Lung Bioavailability of BDP/Formoterol HFA Fixed Combination After Single Administration in 12 Healthy Volunteers Using the Standard Actuator With or Without Charcoal Block or the Aerochamber Spacer.

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Jan 20, 2011
Registry last updated
Aug 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.